Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $15.60 Average Price Target from Brokerages

Key Points

• Y-mAbs Therapeutics, Inc. has received a consensus recommendation of "Moderate Buy" from eleven brokerages, with an average twelve-month price target set at $15.60.
• Recent analyst ratings have varied, with Bank of America lowering the stock to an "underperform" rating and setting a $3.00 target, while others have given it an "outperform" rating with targets as high as $18.00.
• The company reported a quarterly earnings per share of (-0.12), exceeding analysts' estimates, and its revenue for the quarter reached $20.90 million, surpassing the consensus estimate of $19.97 million.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $15.60.

A number of equities analysts have recently commented on the company. Oppenheimer dropped their target price on Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, May 29th. HC Wainwright dropped their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a report on Monday, May 19th. Wedbush restated an "outperform" rating and set a $18.00 price objective (down previously from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th. Bank of America cut Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a report on Tuesday, April 22nd. Finally, Truist Financial dropped their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock traded up $0.09 on Tuesday, reaching $4.97. The company had a trading volume of 232,178 shares, compared to its average volume of 145,025. The firm has a market cap of $225.04 million, a price-to-earnings ratio of -7.77 and a beta of 0.51. The firm's 50-day moving average price is $4.60 and its two-hundred day moving average price is $4.93. Y-mAbs Therapeutics has a 1 year low of $3.55 and a 1 year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. The firm had revenue of $20.90 million during the quarter, compared to analysts' expectations of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 30.59% and a negative net margin of 31.84%. As a group, analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC raised its position in Y-mAbs Therapeutics by 203.0% during the 2nd quarter. CWM LLC now owns 7,121 shares of the company's stock valued at $32,000 after purchasing an additional 4,771 shares in the last quarter. Rhumbline Advisers raised its position in Y-mAbs Therapeutics by 4.8% during the 1st quarter. Rhumbline Advisers now owns 53,909 shares of the company's stock valued at $239,000 after purchasing an additional 2,457 shares in the last quarter. Strs Ohio bought a new stake in Y-mAbs Therapeutics during the 1st quarter valued at $192,000. Acorn Capital Advisors LLC raised its position in Y-mAbs Therapeutics by 13.1% during the 1st quarter. Acorn Capital Advisors LLC now owns 3,235,387 shares of the company's stock valued at $14,333,000 after purchasing an additional 373,562 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in Y-mAbs Therapeutics by 58.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 237,511 shares of the company's stock valued at $1,052,000 after purchasing an additional 87,830 shares in the last quarter. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.